Potential migraine therapy to be presented April 22 by Achelios Therapeutics

Achelios Therapeutics will announce results from a Phase IIa placebo-controlled clinical trial in moderate and severe migraine sufferers treated with TOPOFEN (TM), the company’s proprietary topical anti-migraine therapy. The data to be presented demonstrate that the simple application of a well-known non-steroidal anti-inflammatory drug, using the company’s proprietary formulation on the skin, over the trigeminal nerve branches, can be a safe and effective alternative treatment for patients suffering from acute migraine. —> Read More